Who Do We Serve?
Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma (PDAC)
Ovarian cancer is often called the “silent killer” because over 70% of cases are diagnosed at an advanced stage, leading to a 5-year survival rate of only about 30% in late-stage cases, compared to over 90% when caught early.
OncoGaze™ detects HRD status at biopsy, helping connect Ovarian Cancer patients to the right treatments, faster.
PANCREATIC Cancer Today
90%
HRD is prevalent in 90% of cases of Pancreatic Cancer
Detecting HRD early can significantly impact patient outcomes by guiding timely use of targeted therapies
44%
5-year survival rate when Pancreatic Cancer is localized and detected early
13%
5-year survival rate for late-stage detection in Pancreatic Cancer
64,000
cases/year U.S.
495,000
cases/year worldwide
#1
highest mortality among common cancers
Pancreatic cancer is notoriously silent—often undetected until advanced, inoperable stages.
Who should get tested for HRD?
All Pancreatic Cancer patients should be tested for HRD.
HRD (Homologous Recombination Deficiency) is prevalent in over 90% of cases of Pancreatic Cancer. It is an actionable biomarker in a subset of pancreatic cancers, and identifying it early enables use of PARP inhibitors and platinum-based therapies—both associated with improved outcomes.Why does this matter?
OncoGaze™ accelerates HRD detection directly from routine pathology slides, eliminating delays tied to next-generation sequencing. By delivering results at the point of diagnosis, OncoGaze empowers clinicians to align patients with the most effective therapies from the start—an essential step in improving survival in a cancer where timing is everything.
Acurion's OncoGaze™ delivers fast, accurate genomic insights from pathology slides—accelerating access to targeted therapy for Pancreatic Cancer patients.
The promise of Oncogaze is game changing in pancreatic cancer. The earliest identification of HRD status provides critical information that focuses therapeutic options around a platinum-based regimen. This is particularly important in the management of resectable or borderline resectable settings where an anticancer response to systemic therapy synergizes with surgery.
James L. Abbruzzese, MD
Chief Emeritus, Duke Division of Medical Oncology
Director Emeritus for Clinical Research, Duke Cancer Institute.
MORE READING
[LINKS TO LITERATURE]
Let's move cancer care forward – together.
Explore how Acurion is driving immediate precision for optimal care. Contact us for a demo of OncoGaze™.